ARTICLE | Company News
Progenics, UR Labs Inc. deal
October 1, 2001 7:00 AM UTC
PGNX received an exclusive worldwide license from UR to methylnaltrexone (MNTX), an opioid receptor antagonist in Phase II testing to treat opioid-induced constipation in cancer patients. PGNX said it...